The New York Times errs in discussion of Myriad case

From Court Reaffirms Right of Myriad Genetics to Patent Genes :

A panel of the United States Court of Appeals for the District of Columbia Circuit upheld Myriad’s right to patent “isolated” genes known as BRCA1 and BRCA2, which account for most inherited forms of breast and ovarian cancer.

The court in question is the Court of Appeals for the Federal Circuit.